Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (280 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: hourssubjectssubjectacutemg dl
  Phrases that lowered it: pharmacokineticstypecombinationdays beforetenofovir
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 4% (lowers risk) · Sponsor's track record
• Number of arms: 9 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Phase: 2 (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, urogenital: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin NCT01143246 · started 2010 · scored riskier than 87% of active trials completed
• Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) NCT04460560 · started 2020 · scored riskier than 96% of active trials completed
• A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome NCT01906307 · started 2014 · scored riskier than 97% of active trials terminated
• PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers NCT05431426 · started 2022 · scored riskier than 2% of active trials completed
• FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis NCT02652819 · started 2015 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.